Adaptimmune Therapeutics (ADAP) AI Stock Analysis

• Market Cap: $71.50M
• Dividend Yield: N/A
• Average Volume (3M): 1.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: 883.05%
• EPS Growth: 62.93%
• Country: US
• Employees: 506
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 265,051,600
• 10 Day Avg. Volume: 541,089
• 30 Day Avg. Volume: 1,259,716
• PEG Ratio: 0.00
• Price to Book (P/B): 17.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.23
• Enterprise Value/Market Cap: 18.56
• Enterprise Value/Revenue: 1.97
• Enterprise Value/Gross Profit: 7.53
• Enterprise Value/Ebitda: -6.15
• 1Y Price Target: $1.57
• Price Target Upside: 481.48% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 43 Neutral
• Price Target: $0.50 ▲(85.19%Upside)

The most significant factors impacting Adaptimmune's stock score are its challenging financial performance and valuation, reflecting ongoing losses and high financial risk. Technical analysis shows neutral momentum, while positive operational achievements in the earnings call provide some optimism for future growth. However, financial stability concerns remain a major risk.

Positive Factors

Launch Success

Management is executing the launch well with high apheresis numbers, opening accounts, fast turnaround time, 100% manufacturing success rate and 100% reimbursement.

Revenue Growth

Management anticipates full-year 2025 Tecelra revenue of $35-45M, surpassing the previous sellside consensus estimate of $25M.

Valuation

Adaptimmune is significantly undervalued, given its market cap of $66M.

Negative Factors

Financial Concerns

Capital overhang remains an ongoing concern and until further financial strategies and/or partnerships are implemented, the recommendation is to hold.

Market Challenges

Concerns around loan repayment and a depressed biotech market are impacting the company's outlook.

Operational Uncertainty

Management has expressed doubts about their ability to remain operational.

Adaptimmune Therapeutics Business Overview & Revenue Model

Company Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

How the Company Makes Money

Adaptimmune Therapeutics generates revenue primarily through collaboration agreements, licensing deals, and milestone payments from pharmaceutical partners. These partnerships often involve upfront fees, research funding, and potential royalties on sales of successfully developed therapies. Additionally, the company may earn revenue from government grants or other funding initiatives aimed at supporting innovative cancer treatments. The success of its SPEAR T-cell therapies in clinical trials and regulatory approvals plays a crucial role in its ability to secure lucrative partnerships and revenue opportunities.

Adaptimmune Therapeutics Financial Statement Overview

Summary

Adaptimmune Therapeutics shows significant revenue growth, but ongoing challenges with negative EBIT, net income, and weak cash flows highlight financial instability. The balance sheet reflects high financial risk with negative equity and declining cash reserves, impacting overall financial health.

Income Statement

Adaptimmune Therapeutics shows a significant improvement in revenue over the years, with a recent TTM revenue of $179.6M compared to $3.96M in 2020. However, the company consistently reports negative EBIT and net income, reflecting ongoing challenges in managing operational costs and achieving profitability. Gross profit margins have improved, but the net profit margin remains negative, indicating continued losses. Despite revenue growth, profitability concerns significantly impact the score.

Balance Sheet

The company's balance sheet reveals high financial risk, with negative stockholders' equity in the latest TTM, indicating liabilities exceed assets. The debt-to-equity ratio is unfavorable due to negative equity, and the return on equity is also negative, reflecting ongoing losses. Cash reserves have declined, adding to financial instability. The company's high liabilities and negative equity present substantial financial risks.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, indicating the company's operations are not generating cash. The free cash flow growth rate is negative, suggesting increased cash consumption. The operating cash flow to net income ratio is unfavorable, reflecting inefficiencies in cash generation relative to reported losses. Despite some financing inflows, the cash flow position remains weak, impacting stability.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
179.64M	178.03M	60.28M	27.15M	6.15M	3.96M
	Gross Profit
176.16M	177.96M	50.42M	-100.58M	-104.94M	-87.61M
	EBIT
-65.23M	-68.76M	-138.04M	-163.97M	-162.25M	-133.41M
	EBITDA
-52.48M	-52.66M	-128.20M	-155.59M	-155.68M	-125.81M
	Net Income Common Stockholders
-69.89M	-70.81M	-113.87M	-165.46M	-158.09M	-130.09M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
59.56M	151.60M	146.94M	204.60M	369.58M	368.22M
	Total Assets
158.07M	245.96M	282.62M	328.92M	469.55M	451.14M
	Total Debt
23.30M	74.21M	25.23M	23.08M	25.47M	23.71M
	Net Debt
-17.76M	-16.93M	-118.76M	-84.96M	-124.48M	-33.17M
	Total Liabilities
195.50M	234.11M	243.10M	247.04M	263.58M	109.92M
	Stockholders Equity
-37.43M	11.85M	39.51M	81.88M	205.96M	341.23M
Cash Flow		Free Cash Flow
-110.22M	-75.93M	-145.76M	-171.51M	1.95M	-56.50M
	Operating Cash Flow
-107.86M	-73.21M	-140.88M	-141.77M	10.73M	-53.59M
	Investing Cash Flow
-17.44M	-58.95M	176.54M	89.14M	75.80M	-278.92M
	Financing Cash Flow
24.19M	78.75M	880.00K	12.87M	3.29M	340.05M

Adaptimmune Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADAP, the sentiment is Negative. The current price of 0.27 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.27, and below the 200-day MA of 0.60, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.22 is Neutral, neither overbought nor oversold. The STOCH value of 39.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADAP.

Adaptimmune Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
ADAG	49 Neutral	$92.33M	―	-55.14%	―	-99.43%	-69.40%
ADAP	43 Neutral	$71.50M	―	-273.36%	―	883.05%	62.93%
CLSD	43 Neutral	$62.94M	―	91.63%	―	-55.47%	24.92%
CABA	39 Underperform	$119.25M	―	-73.85%	―	―	-40.59%
CNTX	37 Underperform	$59.97M	―	-55.59%	―	―	65.02%
JSPR	35 Underperform	$86.68M	―	-101.34%	―	―	21.40%

Adaptimmune Therapeutics Corporate Events

Adaptimmune’s Annual Meeting Focuses on Shareholder Engagement

Adaptimmune Therapeutics held its annual general meeting on May 29, 2025, where shareholders voted on several resolutions, including the re-election of directors and the approval of the company’s 2025 Employee and Non-Employee Share Option Schemes. The meeting also determined that advisory votes on executive compensation will be held annually until 2031, reflecting the company’s commitment to shareholder engagement and governance practices.

The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.

Adaptimmune Therapeutics CFO Departure Terms Revised

Adaptimmune Therapeutics announced a variation to the previously agreed termination terms with their Chief Financial Officer, Gavin Wood. His employment will now end on August 31, 2025, due to redundancy, with severance terms including a 12-month salary, pro rata bonus eligibility, and healthcare benefits reimbursement.

Adaptimmune Therapeutics Reports Q4 2024 Business Update

Adaptimmune Therapeutics provided a business update for Q4 and the full year 2024, highlighting the successful launch momentum of its sarcoma franchise product, Tecelra, with 10 patients apheresed in Q1 2025 and 3 in 2024. The company achieved all manufacturing and supply goals and is on track to expand its network of Authorized Treatment Centers by the end of 2025. Additionally, Adaptimmune completed a corporate restructure in February 2025, implementing cost reductions for its PRAME and CD70 programs, and is evaluating strategic options to maximize shareholder value. The company aims for profitability by 2027 while addressing concerns about its ability to continue as a going concern.